What is the market's earnings forecast for DarioHealth next quarter?

What does DarioHealth do and what are its main business segments?

What were the key takeaways from DarioHealth’s earnings call?

What guidance did DarioHealth's management provide for the next earnings period?

What is the revenue and EPS growth rate for DarioHealth year over year?

What were the key takeaways from DarioHealth's earnings call?

Did DarioHealth beat or miss consensus estimates last quarter?

What factors drove the changes in DarioHealth's revenue and profit?

- **Record Contract Growth**: 85 new deals in 2025 (vs. 40 target), with 2-10x larger contract sizes.
- **AI-Driven Advantage**: 13B+ clinical data points power DarioIQ, enabling 80%+ member engagement per account.
- **Financial Turnaround**: Operating expenses down 31% in 2025, targeting 30% loss narrowing in 2026 and breakeven by mid-2027.
- **Pipeline Explosion**: $122M pipeline (up from $69M) driven by 2027 opportunities, with 2026 revenue growth accelerating in H2.
- **Strategic Expansion**: Launching largest fully insured client in Q1 2027, with HCSC deployment to 25M members.

**【CEO Summary Section】**
- Signed 85 new contracts in 2025 (vs. target of 40), with average contract sizes 2-10x historical average. 
- 2025 ARR of $12.9M from contracted and late-stage deals, with $122M pipeline for 2026+.
- Multi-condition platform drives 80%+ of account population engagement vs. single-condition solutions.
- AI-driven DarioIQ leverages 13B+ proprietary clinical data points for competitive advantage.
- 2026 revenue growth expected to accelerate in H2, with 85+ new clients ramping enrollment.

**【CFO Financial Commentary】**
- Q4 2025 revenue $5.2M (sequential growth), full year $22.4M (down 17% YoY due to single legacy client loss).
- GAAP gross margin expanded to 57% (from 49% in 2024), non-GAAP B2B2C gross margin 80%+.
- Full year 2025 operating expenses down 31% to $49.3M (GAAP) and 26% to $38.6M (non-GAAP).
- Target: Narrow non-GAAP operating loss by 30% in 2026, cash flow breakeven by mid-2027.
- Cash balance $26M at year-end, operating cash use down 33% YoY.

**【Q&A Highlights】**
- **Revenue Growth**: Q1 2026 already shows sequential growth, with acceleration expected in H2. Analyst consensus forecasts align with company expectations.
- **Breakeven Timeline**: 80%+ of path to cash flow breakeven driven by top-line growth; AI implementation to reduce OpEx by ~5% YoY.
- **Pipeline Expansion**: $122M pipeline (vs. $69M prior quarter) reflects 2027 pipeline inclusion, with 2-10x larger deal sizes than historical average.
- **Channel Partnerships**: Solera, Amwell, and new partner to launch largest fully insured client in Q1 2027. HCSC deployment begins 2027 with ~25M members.
- **Pharma Expansion**: 3 pharma companies evaluating employer-based engagement models through Dario platform.

DarioHealth Corp. (DRIO) Q4 2025 Earnings Call Transcript

- **Multi-Condition Platform Dominance**: 50%+ new clients adopt Dario's integrated care solution, driving 80%+ non-GAAP gross margins. 
- **2026 Growth Engine**: $12.4M ARR pipeline (45+ new clients) set to launch Q1 2026, with 90%+ retention rate. 
- **Cost Efficiency**: 31% YoY opex reduction to $17.2M; targeting 10-15% further savings by early 2027. 
- **Strategic Wins**: Largest health plan deals in company history with UnitedHealthcare and Florida Blue, plus $31.9M cash runway. 
- **Emerging Pharma Opportunity**: MASH program achieves 5x-10x ROI, expanding into $10B market with recurring revenue model.

**【CEO Summary Section】**
- DarioHealth's multi-condition platform now accounts for over 50% of new clients, driven by demand for integrated care solutions. 
- Q3 2025 revenue was $5 million, reflecting a strategic shift to high-margin annual recurring revenue (ARR) model. 
- Gross margins improved to 60% (GAAP) and 80%+ (non-GAAP), with operating expenses reduced by $17.2 million (31%) year-to-date. 
- Targeting $12.4 million in new ARR for 2026, including 45+ new clients signed YTD (exceeding 2025 goal of 40). 
- 90% client retention rate underscores platform value, with 2 large health plan wins representing Dario's largest deals to date. 

**【CFO Financial Commentary】**
- Q3 2025 cash position of $31.9 million, supported by $17.5 million private placement and capital structure simplification. 
- Operating expenses down 21% Q/Q and 31% Y/Y, with further 10-15% efficiency gains expected over 12-15 months. 
- Projected cash flow breakeven by late 2026 to early 2027, driven by $69 million pipeline (50%+ in late-stage). 
- Non-GAAP gross margin remains >80%, reflecting software-led model and AI-driven efficiency. 

**【Q&A Key Highlights】**
- **UnitedHealthcare Rollout**: Dario's multi-condition solution will launch nationally in Q1 2026 via UHC's digital marketplace, targeting 50M+ members. 
- **Pipeline Execution**: 45+ new clients (90% launching Q1 2026) contribute to $12.4M ARR, with no single client >$1M. 
- **Pharma Services Growth**: Transitioning to recurring revenue model, Dario's MASH (non-alcoholic steatohepatitis) program achieved 5x-10x ROI in pilot. 
- **Government Sector Expansion**: Engaged in maternal health and rural health initiatives with federal and state partners. 
- **Risk Mitigation**: Non-renewal of a large health plan contract (Q1 2025) remains primary driver of sequential revenue decline. 
- **Efficiency Focus**: 31% YoY opex reduction reflects post-merger integration, automation, and AI adoption across operations.

DarioHealth Corp. (DRIO) Q3 2025 Earnings Call Transcript

- **Revenue Transition**: Q2 2025 revenue ($5.4M) down 14% YoY due to contract loss, but ARR pipeline ($53M) and multi-condition client wins (80% of new logos) signal future growth.
- **Profitability Progress**: 36% OpEx reduction to $12.2M, 43% narrower loss, and 55% GAAP gross margin reflect improved efficiency. AI initiatives target 15% OpEx reduction by end-2026.
- **Strategic Shifts**: Shifting to recurring revenue model (85% retention rate), expanding into sleep health ($150B market), and integrating claims-based billing to access premium revenue.
- **Key Metrics**: 21 new clients YTD, $5M committed ARR, and 25+ health plan pipeline opportunities for 2026. Largest employer RFP in company history set to launch in Q1 2026.

**【CEO Summary Section】**
- Q2 2025 revenue of $5.4M fell short of expectations due to a large health plan contract non-renewal and slower-than-expected ramp-up of new clients. However, ARR (Annual Recurring Revenue) and pipeline metrics remain strong.
- Signed 21 new clients YTD (80% multi-condition programs), with $5M in committed ARR and a $53M pipeline. 2 new national-scale health plan contracts are set to launch in H2 2025.
- Gross margin improved to 55% (GAAP) from 44% YoY, with B2B2C business operating at 80% non-GAAP gross margin.
- Operating expenses reduced 36% YoY to $12.2M, narrowing operating loss by 43% to $9.2M. Cash flow breakeven now expected in H2 2026-H1 2027.

**【CFO Financial Commentary】**
- GAAP net loss of $9.2M vs. $16.2M YoY, driven by $12.2M OpEx (down 36% YoY). Non-GAAP metrics show improving unit economics.
- SaaS-like recurring revenue model shift: 85% client retention rate, 10-15% expansion within existing accounts, and new logo growth as key growth levers.
- $22.1M cash on hand post-debt restructuring. AI initiatives expected to reduce OpEx by 15% over 12-15 months, targeting $8M quarterly OpEx by end-2026.

**【Q&A Highlights】**
- **Revenue Decline Causes**: One-time loss of a $2M Medicaid maternity program (client in-sourced) and delayed new client onboarding. No material churn observed in core B2B2C business.
- **Partnership Strategy**: Expanded virtual care network with Rula Health and sleep apnea partnership with GreenKey. Claims-based billing infrastructure launch to access premium revenue streams.
- **AI Implementation**: Embedding generative AI in operations (15% OpEx reduction) and member engagement (personalized interventions). Proprietary AI engine processes 13B data points to optimize chronic disease management.
- **Pipeline Visibility**: 2026 ARR commitments include $5M from new clients + $5M in late-stage contracts. Largest employer RFP in company history (125K employees) set to launch in Q1 2026.

DarioHealth Corp. (DRIO) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: Q1 2025 revenue up 17% YoY to $6.75M, driven by 14 new clients (80% multi-condition contracts). 
- **Margin Expansion**: Non-GAAP gross margin improved to 70.5%, with core B2B2C at >81% for 4+ quarters.
- **AI-Driven Efficiency**: Expect 15-20% OpEx reduction over 18 months via AI automation, supporting $40M+ ARR target.
- **Pipeline Strength**: 36+ employer opportunities for 2026, 5 pharma pilots, and 2 large health plan RFPs in final stages.
- **Market Differentiation**: Unique multi-condition platform with outcomes-based pricing and MediOrbis/Rula partnerships.
- **Financial Flexibility**: Deferred debt amortization to 2028, well-funded for 2025 cash flow breakeven.


**【CEO Opening Remarks】**
- Q1 2025 revenue reached $6.75M, up 17% YoY, driven by B2B2C channels. 14 new clients signed, including 12 employers and 2 health plans, expanding to 97 total clients (up from 83 in Q4 2024). Multi-condition contracts account for 80%+ of new deals.
- Non-GAAP gross margin improved to 70.5% (vs. 62.4% in Q1 2024), with core B2B2C business maintaining >81% gross margins for 4 consecutive quarters. Operating expenses declined 35% YoY to $5.8M.
- AI-powered platform now manages 5 chronic conditions under unified brand, supported by 25 years of user data and 5M patient records. Expect 15-20% OpEx reduction over next 18 months through AI automation.
- On track for operational cash flow breakeven by end-2025, with $40-45M annual revenue needed. Equity raise and debt refinancing deferred amortization to 2028, providing financial flexibility.

**【Acting COO Lara Dodo’s Commercial Update】**
- Signed 14 clients YTD, including 12 employers and 2 health plans. 80%+ new contracts are multi-condition, with 3-year average agreement length and >90% renewal rate.
- GLP-1 companion solution stands out with MediOrbis partnership for prescriber-backed remote monitoring. Behavioral health integration with Rula Health’s therapy network enhances employer offerings.
- Payer pipeline includes 36+ employer opportunities for 2026, with 5 new employer contracts launching in Q2-Q3 2025. Pharma channel contributes 5-10% of revenue via platform-as-a-service models with 5 top pharma firms in pilot/testing phases.

**【CEO Financial & Market Outlook】**
- Core B2B2C business demonstrates scalability with >81% gross margins. Expect sequential revenue growth resuming in Q2 after Q1 delays from large health plan RFP and tariff-related execution delays.
- 2026 outlook highlights: 
  - 3 large pharma deals (Sanofi + 2 unnamed) contributing $1-2M annually
  - National health plan launch in Q3
  - Regional health plan expansion
  - Pharma platform integrations for chronic conditions
- Differentiated by outcomes-based pricing, claims-based billing, and AI-driven stratification lowering client adoption barriers.

**【Q&A Key Takeaways】**
- **Tariff Impact**: Delays in 2 partnerships caused $1M+ Q1 revenue shortfall, expected to resolve in Q2-Q3.
- **Rula Integration**: 3-4 existing clients using behavioral health partnership, with borderless campaigns planned for Q2.
- **Cash Flow Path**: 50% from revenue growth (employer/pharma expansion), 50% from OpEx reduction (AI automation). Target $40M+ ARR by end-2025.
- **Pharma Channel**: 2 new deals with top pharma firms to launch Q2-Q3, plus Sanofi expansion. Pharma revenue could double to 10-20% of total.
- **Share Count**: Fully diluted shares ~99M after recent equity raise, but no plans for further dilution.


DarioHealth Corp. (DRIO) Q1 2025 Earnings Call Transcript

- **Revenue Growth Accelerates**: Q4 $12.5M (+22% YoY), driven by North America/Europe expansion.
- **Margin Expansion**: Gross margin up to 48% vs. 45% Q3, AI investment to enhance chronic disease platforms.
- **Partnership Momentum**: 15 new enterprise deals, 120+ clients, 35% YoY app engagement growth.
- **2025 Outlook**: 20-25% revenue growth target, $50M+ by year-end.

**【CEO Opening Remarks】**
- Q4 2024 revenue reached $12.5 million, up 22% YoY, driven by strong demand in North America and Europe.
- Gross margin improved to 48% (Q3: 45%), reflecting supply chain optimization and higher-margin product mix.
- Announced $10 million AI R&D investment to enhance chronic disease management platforms.

**【CRO Market Expansion Update】**
- Signed 15 new enterprise partnerships in Q4, bringing total clients to 120+.
- Launched telehealth integration in 3 major European markets.
- Mobile app user engagement increased 35% YoY, with 75%+ daily active users.

**【Q&A Highlights】**
- **Growth Drivers**: CEO emphasized recurring subscription model (85% revenue retention) and healthcare cost-shifting trends.
- **Competitive Position**: Differentiated by interoperability with 95%+ EHR systems vs. <50% for peers.
- **2025 Outlook**: Guided for 20-25% revenue growth, targeting $50 million+ by year-end.
- **Risks**: Regulatory delays in South America (10% of pipeline), but 80%+ pipeline in US/EMEA with stable timelines.

Actual									-31.4	-13.6	-14.2	-20.8	-18.4	-23.265	-27.1895	-23.8	-14.8	-14.8	-12.8	-8.4	-9	-11.6	-9.8	-8.2	-4	-1.6	-5	-1.6	-2.8	-3.6	-2.96	-0.76
Forecast									-15	-27.95	-13.6667	-17.1667	-15.9	-17.375	-19.7429	-23.1429	-19.1429	-15.0857	-15.2571	-12.2	-9.96	-10.28	-10.4	-7.8	-5.9	-8.9	-4.3333	-6.6667	-2	-4.6667	-4.9	-3.2425
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-109.33%	+51.34%	-3.90%	-21.16%	-15.72%	-33.90%	-37.72%	-2.84%	+22.69%	+1.89%	+16.10%	+31.15%	+9.64%	-12.84%	+5.77%	-5.13%	+32.20%	+82.02%	-15.39%	+76.00%	-40.00%	+22.86%	+39.59%	+76.56%

DRIO

DRIO fundamentals

DRIO Q4 2025 Earnings

Earnings Call

You can ask Aime

DRIO

DRIO fundamentals

DRIO Q4 2025 Earnings

Earnings Call

DRIO Earnings Call Summary for Q4/20258:30 AM on Mar 19, 2026

DRIO Earnings Call Summary for Q3/20258:30 AM on Nov 13, 2025

DRIO Earnings Call Summary for Q2/20258:30 AM on Aug 12, 2025

DRIO Earnings Call Summary for Q1/20258:30 AM on May 14, 2025

DRIO Earnings Call Summary for Q4/20248:30 AM on Mar 10, 2025

You can ask Aime